Bahram Valamehr, Ph.D., MBA, serves as President, Chief Executive Officer, and Director at Fate Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and immune disorders. With more than 20 years of expertise in cell therapy development, manufacturing, and commercialization, Dr. Valamehr has driven the advancement of scalable, off-the-shelf platforms that address key limitations of conventional cell therapies. He holds a Ph.D. in Chemical and Biomolecular Engineering from Johns Hopkins University and an MBA from Quantic School of Business and Technology. Dr. Valamehr joined Fate Therapeutics in 2015 as Vice President of Process Sciences, swiftly ascending to Senior Vice President of Technical Operations and, in 2020, President and Head of Research & Development. Prior to Fate, he was Vice President of Technical Development at Ocata Therapeutics (formerly Advanced Cell Technology), leading the scale-up of clinical-grade retinal pigment epithelial cells for macular degeneration therapies. His earlier roles included Director of Process Development at StemCells Inc. and Senior Scientist at Sangamo BioSciences, where he specialized in optimizing manufacturing processes for stem cell and gene-edited products. Under Dr. Valamehr's leadership, Fate Therapeutics has achieved pivotal milestones, including the dosing of the first patients in multiple Phase 1 trials for iPSC-derived natural killer (NK) and T-cell programs, such as FT516, FT596, and FT819, in collaboration with partners like Ono Pharmaceutical and Janssen. His strategic vision has secured key alliances, expanded the company's multiplexed engineered cell therapy pipeline, and positioned Fate as a frontrunner in multiplexed gene editing and renewable cell manufacturing, accelerating the path to transformative treatments for hematologic and solid tumor malignancies.